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Abstract
Recent large cancer studies have measured somatic alterations in an unprecedented
number of tumours. These large datasets allow the identification of cancer-related sets
of genetic alterations by identifying relevant combinatorial patterns. Among such
patterns, mutual exclusivity has been employed by several recent methods that have
shown its effectivenes in characterizing gene sets associated to cancer. Mutual
exclusivity arises because of the complementarity, at the functional level, of alterations
in genes which are part of a group (e.g., a pathway) performing a given function. The
availability of quantitative target profiles, from genetic perturbations or from clinical
phenotypes, provides additional information that can be leveraged to improve the
identification of cancer related gene sets by discovering groups with complementary
functional associations with such targets.
In this work we study the problem of finding groups of mutually exclusive alterations
associated with a quantitative (functional) target. We propose a combinatorial
formulation for the problem, and prove that the associated computation problem is
computationally hard. We design two algorithms to solve the problem and implement
them in our tool UNCOVER. We provide analytic evidence of the effectiveness of
UNCOVER in finding high-quality solutions and show experimentally that UNCOVER
finds sets of alterations significantly associated with functional targets in a variety of
scenarios. In particular, we show that our algorithms find sets which are better than the
ones obtained by the state-of-the-art method, even when sets are evaluated using the
statistical score employed by the latter. In addition, our algorithms are much faster
than the state-of-the-art, allowing the analysis of large datasets of thousands of target
profiles from cancer cell lines. We show that on one such dataset from project Achilles
our methods identify several significant gene sets with complementary functional
associations with targets. Software available at:
https://github.com/VandinLab/UNCOVER.
Introduction
Recent advances in sequencing technologies now allow to collect genome-wide
measurements in large cohorts of cancer patients (e.g., [1–6]). In particular, they allow
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the measurement of the entire complement of somatic (i.e., appearing during the
lifetime of an individual) alterations in all samples from large tumour cohorts. The
study of such alterations has lead to an unprecedented improvement in our
understanding of how tumours arise and progress [7]. One of the main remaining
challenges is the interpretation of such alterations, in particular identifying alterations
with functional impact or with relevance to therapy [8].
Several computational and statistical methods have been recently designed to
identify driver alterations, associated to the disease, and to distinguish them from
random, passenger alterations not related with the disease [9]. The identification of
genes associated with cancer is complicated by the extensive intertumour
heterogeneity [10], with large (100-1000’s) and different collections of alterations being
present in tumours from different patients and no two tumours having the same
collection of alterations [10,11]. Two main reasons for such heterogeneity are that
i) most mutations are passenger, random mutations, and, more importantly, ii) driver
alterations target cancer pathways, groups of interacting genes that perform given
functions in the cell and whose alteration is required to develop the disease. Several
methods have been designed to identify cancer genes using a-priori defined
pathways [12] or interaction information in the form of large interaction
networks [13,14].
Recently several methods (see Section ) for the de novo discovery of mutated cancer
pathways have leveraged the mutual exclusivity of alterations in cancer pathways.
Mutual exclusivity of alterations, with sets of genes displaying at most one alteration for
each patient, has been observed in various cancer types [7, 11,15,16]. The mutual
exclusivity property is due to the complementarity of genes in the same pathway, with
alterations in different members of a pathway resulting in a similar impact at the
functional level. Mutual exclusivity has been successfully used to identify cancer
pathways in large cancer cohorts [15,17,18].
An additional source of information that can be used to identify genes with
complementary functions are quantitative measures for each samples such as: functional
profiles, obtained for example by genomic or chemical perturbations [19–21]; clinical
data describing, obtained for example by (quantitative) indicators of response to
therapy; activation measurements for genes or sets of genes, as obtained for example by
single sample scores of Gene Set Enrichment Analysis [22, 23]. The employment of such
quantitative measurements is crucial to identify meaningful complementary alterations
since one can expect mutual exclusivity to reflect in functional properties (of altered
samples) that are specific to the altered samples.
Related work
Several recent methods have used mutual exclusivity signals to identify sets of genes
important for cancer [24]. RME [25] identifies mutually exclusive sets using a score
derived from information theory. Dendrix [26] defines a combinatorial gene set score
and uses a Markov Chain Monte Carlo (MCMC) approach for identifying mutually
exclusive gene sets altered in a large fraction of the patients. Multi-Dendrix [27] extends
the score of Dendrix to multiple sets and uses an integer linear program (ILP) based
algorithm to simultaneously find multiple sets with mutually exclusive alterations.
CoMET [18] uses a generalization of Fisher exact test to higher dimensional contingency
tables to define a score to characterize mutually exclusive gene sets altered in relatively
low fractions of the samples. WExT [18] generalizes the test from CoMET to
incorporate individual gene weights (probabilities) for each alteration in each sample.
WeSME [28] introduces a test that incorporates the alteration rates of patients and
genes and uses a fast permutation approach to assess the statistical significance of the
sets. TiMEx [29] assumes a generative model for alterations and defines a test to assess
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Fig 1. Identification of mutually exclusive alterations associated with a
target profile.
Alterations in the green set have high mutual exclusivity but no association with the
target profile. Alterations in the orange set have lower mutual exclusivity but strong
association with the target profile. Methods that find mutually exclusive sets of
alterations without considering the target profile will identify the green set as the most
important gene set.
the null hypothesis that mutual exclusivity of a gene set is due to the interplay between
waiting times to alterations and the time at which the tumor is sequenced. MEMo [17]
and the method from [30] employ mutual exclusivity to find gene sets, but use an
interaction network to limit the candidate gene sets. The method by [31] and
PathTIMEx [32] introduce an additional dimension to the characterization of
inter-tumor heterogeneity, by reconstructing the order in which mutually exclusive gene
sets are mutated. None of these methods take quantitative targets into account in the
discovery of significant gene sets and sets showing high mutual exclusivity may not be
associated with target profiles (Fig. 1).
[33] recently developed the repeated evaluation of variables conditional entropy and
redundancy (REVEALER) method, to identify mutually exclusive sets of alterations
associated with functional phenotypes. REVEALER uses as objective function (to score
a set of alterations) a re-scaled mutual information metric called information coefficient
(IC). REVEALER employs a greedy strategy, computing at each iteration the
conditional mutual information (CIC) of the target profile and each feature, conditioned
on the current solution. REVEALER can be used to find sets of mutually exclusive
alterations starting either from a user-defined seed for the solution or from scratch,
and [33] shows that REVEALER finds sets of meaningful cancer-related alterations.
Our contribution
In this paper we study the problem of finding sets of alterations with complementary
functional associations using alteration data and a quantitative (functional) target
measure from a collection of cancer samples. Our contributions in this regard are
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fourfold. First, we provide a rigorous combinatorial formulation for the problem of
finding groups of mutually exclusive alterations associated with a quantitative target
and prove that the associated computational problem is NP-hard. Second, we develop
two efficient algorithms, a greedy algorithm and an ILP-based algorithm to identify the
set of k genes with the highest association with a target; our algorithms are
implemented in our method fUNctional Complementarity of alteratiOns discoVERy
(UNCOVER). Third, we show that our algorithms identify highly significant sets of
genes in various scenarios; in particular, we compare UNCOVER with REVEALER on
the same datasets used in [33], showing that UNCOVER identifies solutions of higher
quality than REVEALER while being on average two order of magnitudes faster than
REVEALER. Interestingly, the solutions obtained by UNCOVER are better than the
ones obtained by REVEALER even when evaluated using the objective function (IC
score) optimized by REVEALER. Fourth, we show that the efficieny of UNCOVER
enables the analysis of a large dataset from Project Achilles with thousands of target
measurements and tens of thousands of alterations. On such dataset UNCOVER
identifies identifies several statistically significant associations between target values and
mutually exclusive alterations in genes sets sets, with an enrichment in well-known
cancer genes and in known cancer pathways.
Materials and methods
This section describes the problem we study and the algorithms we designed to solve it,
that are implemented in our tool UNCOVER. We also describe the data and
computational environment for our experimental evaluation.
UNCOVER: Functional complementarity of alterations
discovery
The workflow of our algorithm UNCOVER is presented in Fig. 2. UNCOVERtakes in
input information regarding 1. the alterations measured in a number of samples (e.g.,
patients or cell lines), and 2. the value of the target measure for each patient.
UNCOVER then identifies the set of mutually exclusive alterations with the highest
association to the target, and employs a permutation test to assess the significance of
the association. Details regarding the computational problem and the algorithms used
by UNCOVER are described in the following sections. The implementation of
UNCOVER is available at https://github.com/VandinLab/UNCOVER.
Computational problem
Let J = {j1, . . . , jm} be the set of samples and let G = {g1, . . . , gn} be the set of genes
for which we have measured alterations in J . We are also given a target profile, that is
for each sample j ∈ J we have a target value wj ∈ R which quantitatively measures a
functional phenotype (e.g., pathway activation, drug response, etc.). For each sample
j ∈ J we also have information on whether each g ∈ G is altered or not in j. Let Ag be
the set of patients in which gene g ∈ G is mutated. We say that a patient j ∈ J is
covered by gene g ∈ G if j ∈ Ag i.e. if gene g is mutated in sample j. Given a set of
genes S ⊂ G, we say that sample j ∈ J is covered by S if j ∈ ∪g∈SAg.
The goal is to identify a set S of at most k genes, corresponding to k subsets
S1, S2, . . . Sk where for each subset Si we have that Si ⊆ J , such that the sum of the
weights of the elements covered by S is maximized. We also penalize overlaps between
sets when an element is covered more than once by S by assigning a penalty pj for each
of the additional times j is covered by S. As penalty we use the positive average of the
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Fig 2. UNCOVER: Functional complementarity of alterations discovery.
UNCOVER takes in input the alterations information and a target profile for a set of
samples, and identifies the set of complementary alterations with the highest association
to the target by solving the Target Associated k-Set problem and performing a
permutation test.
normalized target values if the original weight of the element was positive. If the
original weight of the element was negative we assign a penalty equal to its weight.
Let cS(j) be the number of sets in S1, . . . , Sk that cover element j ∈ J .
Therefore for a set S of genes, we define its weight W (S) as:
W (S) =
∑
j∈∪s∈SAs
wj −
∑
j∈∪s∈SAs
(cS(j)− 1)pj
The Target Associated k-Set problem: Given a set J of samples, sets Ag1 , . . . , Agn
describing alterations of genes G = {g1, . . . , gn} in the set J , weights wj and penalties
pj > 0 for each sample j ∈ J find the S of ≤ k elements maximizing W (S).
The following results defines the computational hardness of the problem above.
Theorem 1. The Target Associated k-Set problem is NP-hard.
Proof. The proof is by reduction from the Maximum Weight Submatrix Problem
(MWSP) defined and proved to be NP-hard in [34]. The MSWP takes as input an m×n
binary matrix A and an integer k > 0 and requires to find the m× k column sub-matrix
Mˆ of A that maximizes the objective function |Γ(M)| − ω(M), where Γ(M) is the set of
rows with at least one 1 in columns of M and ω(M) =
∑
g∈M |Γ({g})| − |Γ(M)|.
Given an instance of Maximum Weight Submatrix Problem, we define an instance of
the Target Associated k-Set as follow: the set of samples J corresponds to the rows of
A, the set of genes G corresponds to the columns of A, and the set Sg of samples
covered by gene g ∈ G is the subset of the rows in which g has a 1. By setting wj = 1
and pj = 1 for all j ∈ J , we have that the objective function of MWSP corresponds to
the weight W (S) for the Target Associated k-Set therefore the optimal solution of the
Target Associated k-Set corresponds to the optimal solution of MWSP.
ILP formulation
In this subsection we provide an ILP formulation for the Target Associated k-Set
problem. Let xi be a binary variable equal to 1 if set i ∈ G is selected and xi = 0
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otherwise. Let zj be a binary variable equal to 1 if element j is covered and zj = 0
otherwise. Let yj denote the number of sets in the solution covering element j. Finally,
let wj be the weight of element j and pj be the penalty for element j
In our ILP formulation, the following constraints need to be satisfied by a valid
solution:
• the total number of sets in the solution is at most k:
∑
i xi ≤ k
• for each element j ∈ J we have: yj =
∑
i:j∈Si xi
• for each element j ∈ J , if j is covered by the current solution then the number of
times j is covered in the solution is at least 1: yj ≥ zj
• for each element j ∈ J , if j is covered by at least one element in the current
solution then j is covered: zj ≥ yj/k.
With the variables defined above, the score for a given solution is
z(q) = max
m∑
j=1
(wj + pj)zj −
m∑
j=1
pjyj . (1)
z(q) constitutes the objective function of our ILP formulation.
Greedy algorithm
Since solving ILPs can be impractical for very large datasets, we also design a k-stage
greedy algorithm to solve the Target Associated k-Set problem. During each stage the
algorithm picks 1 set Ai to be part of the solution; this is done by first computing the
total weight of each subset which is defined as the sum of the weights of its elements
W (Ai) =
∑
j∈Ai wj . Then the algorithm finds the subset Ai of maximum positive
weight and adds it to the solution. It may be that at some stage ` no additional set of
positive weight can be selected, in this case, the solution obtained after stage `− 1 will
be our output. At the end of the iteration the weight of every element j that belonged
to the chosen set Ai is set to the negative of penalty pj , in order to penalize future
selections of the same elements. The greedy algorithm is described in Algorithm 1.
Input: A set of elements J (samples), a class I of subsets of J (genetic alterations)
and an integer k (number of alterations we want to find). Each element
j ∈ J has an associated weight wj (target profile) and a penalty pj .
Output: k subsets, S1, S2, . . . Sk , where each subset selected is a member of I,
such that the sum of the weights of the elements in the selected sets is
maximized and the overlap between selected sets is minimized.
for `← 1 to k do
for i← 1 to n do W (Ai)←
∑
j∈Ai wj ;
S` ← arg maxAi>0{W (Ai)};
for j ∈ S` do wj ← −pj ;
end
return S1 . . . Sk;
Algorithm 1: Greedy Coverage
We note that our greedy algorithm is analogous to the greedy algorithm for the
Maximum k-Coverage problem [35] with the difference that rather than eliminating the
elements already selected we change their weight to a penalty. Also, assuming it is
acceptable to return less than k sets, we only pick a set if it has a positive weight. The
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running time of the algorithm is O(kmn) where m = number of samples and n =
number of alterations.
While the greedy algorithm may not return the optimal solution, we prove that it
provides guarantees on the weight of the solution it provides.
Proposition 1. Let S∗ the optimal solution of the Target Associated k-Set and Sˆ be
the solution returned by the greedy algorithm. Then W (Sˆ) ≥W (S∗)/k.
Proof. Note that the weight of subsets in the optimal solution W (S∗) can only be lower
compared to the original weight of the subsets, since the only weight update operation
performed is to substitute positive weights of elements selected with a negative penalty.
The first subset Sˆ1 selected by our algorithm is the set of maximum weight out of all
subsets and therefore W (Sˆ1) ≥W (S∗` ) for ` = 1..k. By the pigeonhole principle, one of
these subsets in the optimal solution must cover at least W (S∗)/k worth of elements.
Thus W (Sˆ1) ≥W (S∗)/k. Therefore the first subset selected by the algorithm already
gives a 1/k approximation of the optimal solution. In subsequent iterations of the
algorithm we only pick additional sets if they have a positive weight so our
approximation ratio can only improve.
We also prove that the bound above is tight
Proposition 2. There are instances of the Target Associated k-Set such that
W (Sˆ) = W (S∗)/k.
The proof is in the Supplementary Material.
While the proposition above is based on an extreme example, our experimental
analysis shows that in practice the greedy algorithm works well and often identifies the
optimal solution. We therefore analyze the greedy algorithm under a generative model
in which there is a set H of k genes with mutually exclusive alterations associated with
the target, while each genes g ∈ G \H is mutated in sample j with probability pg
independently of all other events. We also assume that the weights wj are such that∑
j∈J wj = 0 and for each j : |wj ≤ 1|. (In practice this is achieved by normalizing the
target values before running the algorithm, by subtracting to each wj the average value∑
j∈J wj/m and then dividing the result by the maximum of the absolute values of the
transformed wj ’s.) Note that this last condition implies that |pj | ≤ 1 for all j. We also
assume that for genes in H the following assumptions hold:
• the set H has an association with the target, i.e.: E[W (H)] ≥ mc′ for a constant
c′ ≥ 1.
• each gene of H contributes to the weight of H, i.e. for each S ⊂ H and each
g ∈ H \ S we have E[W (S ∪ {g})]−E[W (S)] ≥ W (H)
kc′′
for a constant c
′′ ≥ 1.
The following shows that, if enough samples from the generative model are
considered, the greedy algorithm finds the set H associated with the target with high
probability.
Proposition 3. If m ∈ Ω (k2 ln(n/δ)) samples from the generative model above are
provided to the greedy algorithm, then the solution of the greedy algorithm is H with
probability ≥ δ.
The proof is in the Supplementary Material.
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Statistical significance
To assess the significance of the solution reported by our algorithms we use a
permutation test in which the dependencies among alterations in various genes are
maintained, while the association of alterations and the target is removed. In particular,
a permuted dataset under the null distribution is obtained as follows: the sets Ag, g ∈ G
are the same as observed in the data; the values of the target are randomly permuted
across the samples.
To estimate the p-value for the solutions obtained by our methods we used the
following standard procedure: 1) we run an algorithm (ILP or greedy) on the real data
D, obtaining a solution with objective function oD; 2) we generate N permuted datasets
as described above; 3) we run the same algorithm on each permuted dataset; 4) the
p-value is the given by (e+ 1)/(N + 1), where e is the number of permuted datasets in
which our algorithm found a solution with objective function ≥ oD.
Data and computational environment
Alteration Data. We downloaded data for the Cancer Cell Line Encyclopedia on
25th September, 2017 from http://www.broadinstitute.org/ccle. In particular we
used the mutation (single nucleotide variants) and copy number aberrations (CNAs)
which are derived from the original Cancer Cell Line Encyclopedia (CCLE) mutations
and CNA datasets. The file we used is CCLE MUT CNA AMP DEL 0.70 2fold.MC.gct. It
consists of a binary (0/1) matrix across 1,030 samples and 48,270 gene alterations in the
form of mutations, amplifications and deletions, with a 1 meaning that the alteration is
present in a sample, and a 0 otherwise.
Target Data. In terms of target values we use the same datasets used by [33] to
compare the performance of UNCOVER with REVEALER. In particular we used the
following files available through the Supplementary Material of [33]:
CTNBB1 transcriptional reporter.gct, which consists of measurements of a
β-catenin reporter in 81 cell lines; NFE2L2 activation profile.gct, which includes
NFE2L2 enrichment profiles for 182 lung cell lines; MEK inhibitor profile.gct,
which contains MEK-inhibitor PD-0325901 sensitivity profile in 493 cancer cell lines
from the Broad Novartis CCLE14l; and KRAS essentiality profile.gct, which
corresponds to the feature KRAS from a subset of 100 cell lines from the Achilles
project dataset. In all these cases we considered the same direction of association
(positive or negative) between alterations and the target as in [33]. Since our algorithm
is very efficient we then decided to run it on a large dataset from Project
Achilles (https://portals.broadinstitute.org/achilles), that uses genome-scale
RNAi and CRISPR-Cas9 perturbations to silence or knockout individual genes. In
particular, we use the whole 2.4.2 Achilles dataset (Achilles QC v2.4.3.rnai.Gs.gct)
available from the project website. This dataset provides phenotype values for 5711
targets, corresponding to genes silenced by shRNA. The phenotype values correspond to
ATARiS [37] gene (target) level scores, quantifying the cell viability when the target
gene is silenced by shRNA. These scores are provided for 216 cell lines [19], with 205 of
them appearing in CCLE.
Data Preprocessing. To be consistent with REVEALER we discarded features with
high or low frequency, in particular features present in less than 3 samples or more than
50 samples were excluded from our analyses. The only exception was the MEK-inhibitor
example, where the high frequency threshold was changed to be 100 since the number of
original samples was substantially higher (i.e., 493) for this case. From the Achilles
dataset we excluded targets that have at least one missing value, in particular in this
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case we exclude 21 of the 5711 sets of target scores. In all our experiments we
normalized the target values before running the algorithm, by subtracting to each weight
wj the average value
∑
j∈J wj/m and dividing the result by the standard deviation of
the (original) wj ’s, in order to have both positive and negative target values.
Simulated Data. We investigated how effective UNCOVER is at finding selected
alterations in a controlled setting, where the ground truth is known. We generated
target values according to a normal distribution with mean 0 and standard deviation 1.
We tested dataset with 200, 600, 1000 and 10000 samples. For each dataset we
considered the 38002 gene alterations present in CCLE and for each of them we placed
alterations in the samples independently of all other events with the same frequencies as
they appear in CCLE. To be consistent with the preprocessing done on rel data we
filtered alterations to only have alterations with frequencies between 0.1 and 0.25. We
also generated a set T of 5 features to have an association with the target values. This
association was varied throughout the experiments to cover different percentages of
positive and negative targets. In particular we generated the selected features to cover
100%, 80%, 60%, 40% of the positive target values and 5%, 10%, 15%, 20% of the
negative target values respectively, chosing random subsets of samples with positive or
negative target values. We will refer to the parameter indicating the percentage of
samples with positive target values selected as P and to the parameter for the
percentage of samples with negative target values selected as N . We divided the
number of targets covered by each of the 5 mutations equally.
Computing Environment and Solver Configuration. To describe and solve an
ILP we used AMPL 20150516 and CPLEX 12.6.3. All parameters in CPLEX were left
at their default values. We implemented our greedy algorithm in Python 3.6.1. We run
our experiments (with the exception of experiments conducted on simulated data) on a
MacBook Air with 1.7 GHz Intel Core i7 processor, 8 GB RAM and 500 GB of local
storage. In order to make a time comparison with REVEALER we also run the R code
provided in [33] on the same machine, using R 3.3.3. All the parameters were left at
their given values except for the number of permutations used to calculate their p-value,
which we changed in order to compare the running time of the methods excluding the
time needed to compute p-values. Experiments on simulated data were conducted on
local nodes of a computing cluster. Each node had the following configuration: four 2.27
GHz CPUs, 5.71 GB RAM and 241 GB of storage.
Results and discussion
We tested UNCOVER on a number of cancer datasets in order to compare its results
with state-of-the-art algorithms and to test whether UNCOVER allows the analysis of
large datasets. In particular we used four datasets described in [33] to compare
UNCOVER with REVEALER, and then performed a large scale analysis using targets
from the Achilles project dataset and alterations from the Cancer Cell Line
Encyclopedia (CCLE).
Comparison with REVEALER
We run the greedy algorithm and the ILP from UNCOVER on the same four datasets
considered by the REVEALER publication [33]. We used the same values of k used
in [33], that is k = 3 for all the datasets, except from the KRAS dataset where k = 4
was used. For each dataset we recorded the solution reported by the greedy algorithm,
the solution reported by the ILP, the value of the objective functions for such solutions
March 28, 2018 9/24
and the running time to obtain such solutions. For ILP solutions, we also performed the
permutation test (see Materials and methods) to compute a p-value using 1000
permutations. The results are reported in Table 1, in which we also show the results
from REVEALER (without initial seeds). Fig. 3 shows alteration matrices and the
association with the target for the solutions identified by UNCOVER.
(a) KRAS essentiality: ILP and Greedy (b)  -catenin target: ILP and Greedy
(c) MEK Inhibitor: ILP (d) MEK Inhibitor: Greedy
(e) NFE2L2 activation: ILP and Greedy
Figure 2: Results of UNCOVER on four cancer datasets from [?]. (a) Solution found by ILP and greedy for KRAS
essentiality target. (b) Solution found by ILP and greedy for  -catenin activation target. (c) Solution found by ILP for
MEK inihibitor target. (d) Solution found by greedy for MEK inihibitor target. (e) Solution found by ILP and greedy
for NFE2L2 activation target. Each panel shows the value of the target (top row) for various samples (columns), with
red being positive and blue being negative values. For each gene in the solution, alterations in each sample are shown
in dark blue, while samples not altered are in light blue. The last row shows the alteration profile of the entire solution.
As expected, the value of the objective function we use is much lower for solutions from REVEALER than
for solutions from our algorithm.
We then compared the solutions obtained by our algorihtms with the solutions from REVEALER in
terms of the information coefficient (IC), that is the target association score used in [?] as a quality of the
solution. Surprisingly, in two out of four datasets our methods, which do not consider the IC score, identify
solutions with IC score higher (by at least 5%) than the solutions reported by REVEALER. For the other
two cases, in one dataset the IC score is very similar (0.50 vs 0.49) while in the other case the IC score
by REVEALER is higher (0.7 vs 0.67) but the solution reported by REVEALER differs from the solution
reported by UNCOVER by 1 gene only. Interestingly, the latter is the only case where the solution from the
ILP has a p-value > 0.1 (p < 0.03 in all other cases), and therefore the solutions (by our methods and by
REVEALER) for such dataset may be, at least in part, due to random fluctuations of the data.
These results show that UNCOVER identifies solutions that better than REVEALER when evaluated
using our objective function and also when evaluated according to the objective function of REVEALER
with a running time that is on average two orders of magnitude smaller than required by REVEALER.
3.3 Analysis of Achilles project data
The efficiency of UNCOVER renders the analysis of a large number of targets, such as the ones available
through the Achilles project, possible. We have run the ILP on the whole Achilles dataset for k = 3, look-
ing for both positive and negative association with target values. After preprocessing the dataset included
5690 functional phenotypes as targets, and for each of these the CCLE provides alteration information for
9
Fig 3. esults of UNCOVER on four cancer datasets from [33].
(a) Solution found by ILP and greedy for KRAS essentiality target. (b) S lution found
by ILP and greedy for β-catenin activation target. (c) Solution found by IL for MEK
inihibitor target. (d) Solution found by greedy for MEK inihibitor target. (e) Solution
found by ILP and greedy for NFE2L2 activation target. Each panel shows the value of
the target (top row) for various samples (columns), with red being positive and blue
being negative values. For each gene in the solution, alterations in each sample are
shown in dark blue, while samples not altered are in light blue. The last row shows the
alteration profile of the entire solution.
We can see that he greedy algorithm identifies the same s lution of the ILP based
a gorithm in three out of four cases, and that the ru time of the ILP and the runtime of
greedy algorithm are comparable and very low (< 40 seconds) in all cases. In contrast,
the running time of REVEALER is much higher (> 1000 seconds in most cases). (We
included all preprocessing in the reported runtimes in table 1 to ensure a fair
comparison with REVEALER; not including preprocessing our running times are all
under 10 seconds.) Comparing the alteration matrices of the solutions by UNCOVER
and the ones of solutions by REVEALER (Supplementary Fig. 7) we note that
alterations in solutions by UNCOVER tend to have higher mutual exclusivity and to be
more concentrated in high weight samples than alterations in solutions by REVEALER.
As expected, the value of the objective function we use is much lower for solutions from
REVEALER than for solutions from our algorithm.
We then compared the solutions obtained by our algorihtms with the solutions from
REVEALER in terms of the information coefficient (IC), that is the target association
score used in [33] as a quality of the solution. Surprisingly, in two out of four datasets
UNCOVER, which does not consider the IC score, identifies solutions with IC score
higher (by at least 5%) than the solutions reported by REVEALER. For the other two
cases, in one dataset the IC score is very similar (0.50 vs 0.49) while in the other case
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Table 1. Comparison of our algorithms with REVEALER.
NFE2L2 activation MEK-inhibitor KRAS essentiality β-catenin activation
ILP solution KEAP1.MC MUT BRAF.V600E MUT KRAS.G12 13 MUT APC.MC MUT
ATP11B AMP KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
SPINT4 DEL NRAS MUT ATP8A2 AMP SLITRK1 AMP
C8orf22 AMP
Objective value 46.17 108.32 28.00 22.97
IC score 0.58 0.49 0.63 0.67
p-value 0.000999 0.000999 0.025974 0.1068931
Running time (s) 14 39 9 9
Greedy solution KEAP1.MC MUT BRAF MUT KRAS.G12 13 MUT APC.MC MUT
ATP11B AMP KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
SPINT4 DEL NRAS MUT ATP8A2 AMP SLITRK1 AMP
C8orf22 AMP
Objective value 46.17 104.29 28.00 22.97
IC score 0.58 0.5 0.63 0.67
Running time (s) 15 35 9 8
REVEALER solution KEAP1.MC MUT BRAF MUT KRAS.G12 13 MUT APC.MC MUT
LRP1B DEL KRAS.G12 13 MUT ZNF385B AMP CTNNB1.MC MUT
OR4F13P AMP NRAS MUT LINC00340 DEL ITGBL1 AMP
NUP153 MUT
Objective value 30.35 104.29 21.86 22.12
IC score 0.54 0.5 0.6 0.7
Running time (s) 1615 4965 1243 787
For each of the four targets (NFE2L2 activation, MEK-inhibitor, KRAS essentiality, β-catenin activation) considered in [33],
the set of alterations of cardinality k reported by our ILP algorithm, by our greedy algorithm, and by REVEALER (without
seeds) is reported. k is chosen as in [33]. For each pair (algorithm, target) we also report the (objective) value of our objective
function for the solution, the value of the IC score (that is, the objective function used in [33]), and the running time of the
algorithm for the target. For solutions found by our ILP we also report the p-value computed by permutation test using 1000
permutations.
the IC score by REVEALER is higher (0.7 vs 0.67) but the solution reported by
REVEALER differs from the solution reported by UNCOVER by 1 gene only.
Interestingly, the latter is the only case where the solution from the ILP has a p-value
> 0.1 (p < 0.03 in all other cases), and therefore the solutions (by our methods and by
REVEALER) for such dataset may be, at least in part, due to random fluctuations of
the data.
In most cases the solutions by UNCOVER and by REVEALER are very similar,
with cancer relevant genes identified by both methods. For NFE2L2 activation, both
methods identify KEAP1, a repressor of NFE2L2 activation [38]. For MEK-inhibitor,
both methods find BRAF, KRAS, and NRAS, three well knwon oncogenic activators of
the MAPK signaling pathway, which contains MEK as well. For KRAS essentiality,
both methods report mutations in KRAS in the solution. For β-catenin activation, both
methods identify CTNNB1 mutations and APC mutations, that is known to be
associated to β-catenin activation [39]. These results show that UNCOVER identifies
relevant biological solutions that are better than the ones identified by REVEALER
when evaluated using our objective function and also when evaluated according to the
objective function of REVEALER with a running time that is on average two orders of
magnitude smaller than required by REVEALER.
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Results on simulated data
For each combination we generated 10 simulated dateset as described in Materials and
methods. Each dataset contains a planted set of 5 alterations associated with the target.
We used both the greedy algorithm and the ILP from UNCOVER with k = 5 to
attempt to find the 5 correct alteration, and evaluated our algorithms both in terms of
fraction of the correct (i.e., planted) solution reported and running time.
As shown in Fig. 4, the greedy algorithm is faster than the ILP for all datasets, and
the difference in running time increases as the number m of samples increases, with the
runtime of the greedy algorithm being almost two order of magnitude smalle than the
runtime of the ILP for m = 1000 samples. In addition, for a fixed number of samples
and alterations, the running time of the greedy algorithm is constant, that is it does not
depend on the properties of the planted solution, while the running time of the ILP
varies greatly depending on these parameters. For m = 10, 000 samples the running
time of the ILP becomes extremely high, so we restricted to consider only two sets of
paramters (p− n = 0.95 and p− n = 0.2). In this case the ILP took between 44 minutes
and 7 hours to complete, while the greedy algorithm terminates in 5 minutes.
In terms of the quality of the solutions found, as expected the ILP outperforms the
greedy (Fig. 5) but the difference among the two tends to disappear when the number
of samples is higher. In addition, since the ILP finds the optimal solution, we can see
that for a limited number of samples we may not reliably identify the planted solution
with 200 samples unless the planted solution appears almost only in positive targets and
in almost all of them (p− n = 0.95), while for m=1000 we can reliably identify the
planted solution using both the ILP and the greedy algorithm even when the association
with the target is weaker (p− n = 0.6). When m = 10, 000, both the ILP and the
greedy algorithm perform well in terms of the quality of the solution: the ILP finds the
correct alterations on every experiment and the greedy identifies the whole planted
solution in all experiments but one for p− n = 0.2, for which it still reports a solution
containing 4 genes in the planted solution.
These results show that for a large number of samples the greedy algorithm reliably
identifies sets of alterations associated with the target, as predicted by our theoretical
analysis, and is much faster than the ILP. For smaller sample size the ILP identifies
better solutions than the greedy and has a reasonable running time.
Analysis of Achilles project data
The efficiency of UNCOVER renders the analysis of a large number of targets, such as
the ones available through the Achilles project, possible. After preprocessing the dataset
included 5690 functional phenotypes as targets, and for each of these the CCLE
provides alteration information for 205 samples and 31137 alterations. In total we have
therefore run 10380 instances (i.e., 5690 targets screened for positive and for negative
associations) looking for both positive and negative association with target values. Since
the number of samples (205) is relatively small, we have run only the ILP from
UNCOVER on the whole Achilles dataset and looked for solutions with k = 3 genes.
The runtime of UNCOVER to find both positive and negative associations, including
preprocessing, is 24 hours. Based on the runtime required on the instances reported
in [33] (see the Comparison with REVEALER section), running REVEALER on this
dataset would have required about 5 months of compute time.
To identify statistically significant associations with targets in the Achilles project
dataset we used a nested permutation test. We first run the permutation test with 10
permutations on all instances (i.e., on all targets for both positive association and
negative association). We then considered all the instances with the lowest p-value
(1/11) and performed a permutation test with 100 permutations only for such instances.
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Fig 4. Running time of UNCOVERon simulated data.
The running time (expectation and standard deviation) of the greedy algorithm and of
the ILP approach are shown for different number of samples and the difference p− n
between the percentage p of samples with positive target and the percentage n of
samples with negative target covered by the the correct solution.
We the iterated such procedure once more, selecting all the instances with lowest
p-value (1/101) and performing a permutation test with 1000 permutations only for
such instances. For positive association we found 60 solutions with p-value < 0.001, and
for negative association we found 102 solutions with p-value < 0.001. The solutions with
p-value < 0.001 (with 1000 permutations) are reported in Supplementary Table 2 and 3.
See Supplemental Fig. 8 for some corresponding alteration matrices.
The genes in the solutions by UNCOVER with p-value 1/1001 are enriched
(p = 2× 10−12 by Fisher exact test) for well-known cancer genes, as reported in [11].
We also tested whether genes in solutions by UNCOVER (with p-value 1/1001) are
enriched for interactions, by comparing the number of interactions in iRefIndex [40]
among genes in such solution with the number of interactions in random sets of genes of
the same cardinality. Genes in solutions by UNCOVER are significantly enriched in
interactions (p = 7× 10−3 by permutation test). In addition, the genes in solutions by
UNCOVER are also enriched in genes in well-known pathways: 12 KEGG pathways [41]
have a significant (corrected p ≤ 0.05) overlap with genes in solutions by UNCOVER
and four of these (endometrial cancer, glioma, hepatocellular carcinoma, EGFR tyrosine
kinase inhibitor resistance) are cancer related pathways. In addition, the targets (i.e.,
genes) with solutions of p-value 1/1001 are enriched (p = 10−3 by permutation test) for
interactions in iRefIndex and for well-known cancer genes as reported in [11]. These
results show that UNCOVER enables the identification of groups of well known cancer
genes with significant associations to important targets in large datasets of functional
target profiles. For example, for target (i.e., silenced gene) TSG101, related to cell
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Fig 5. Quality of solutions of UNCOVERon simulated data.
The fraction of genes in the planted (i.e., correct) solution found by the greedy
algorithm and by the ILP approach are shown for different number of samples and the
difference p− n between the percentage p of samples with positive target and the
percentage n of samples with negative target covered by the the correct solution.
Fig 6. Solution by UNCOVER for silencing of TSG101 (data from Achilles
Project).
The alteration matrix of genes in the solution identified by UNCOVER as associated to
reduced cell viability is reported. The figure shows the value of the target (top row) for
various samples (columns), with blue being negative values (i.e., reduced cell viability)
and red being positive values. For each gene in the solution, alterations in each sample
are shown in dark blue, while samples not altered are in light blue. The last row shows
the alteration profile of the entire solution.
growth, UNCOVER identifies the gene set shown in Figure 6 as associated to reduced
cell viability. ERBB2 is a well known cancer gene and CDH4 is frequently mutated in
several cancer types, and both are associated to cell growth.
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Conclusion
In this work we study the problem of identifying sets of mutually exclusive alterations
associated with a quantitative target profile. We provide a combinatorial formulation
for the problem, proving that the corresponding computational problem is NP-hard. We
design two efficient algorithms, a greedy algorithm and an ILP-based algorithm, for the
identification of sets of mutually exclusive alterations associated with a target profile.
We provide a formal analysis for our greedy algorithm, proving that it returns solutions
with rigorous guarantees in the worst-case as well under a reasonable genarative model
for the data. We implemented our algorithms in our method UNCOVER, and showed
that it finds sets of alterations with a significant association with target profiles in a
variety of scenarios. By comparing the results of UNCOVER with the results of
REVEALER on four target profiles used in the REVEALER publication [33], we show
that UNCOVER identifies better solutions than REVEALER, even when evaluated
using REVEALER objective function. Moreover, UNCOVER is much faster than
REVEALER, allowing the analysis of large datasets such as the dataset from project
Achilles, in which UNCOVER identifies a number of associations between functional
target profiles and gene set alterations. Our tool UNCOVER (as well as REVELEAR)
relies on the assumption that the mutual exclusivity among alterations is due to
functional complementarity. Another explanation for mutual exclusivity is the fact that
each cancer may comprise different subtypes, with different subtypes being
characterized by different alterations [27]. UNCOVER can be used to identify sets of
mutually exclusive alterations associated with a specific subtype whenever the subtype
information is available, by assigning high weight to samples of the subtype of interest
and low weight to samples of the other subtypes.
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Supplementary Material
Proposition 4. There are instances of the Target Associated k-Set such that
W (Sˆ) = W (S∗)/k.
Proof. To see that the bound is tight just consider the following example. We want to
pick k sets out of n sets A1...An. Sets A1...Ak include 2 elements of respective weight
a ≥ 0 and b = a/(k − 1). Subset Ak+1 includes all the elements of weight b from the
previous k sets and one element with a small weight . Each of the remaining sets
Ak+2...An include an arbitrary number of elements with overall weight ≤ 0. We choose
a penalty of value a. Note that one can choose the weights of elements in sets
Ak+2...An in such a way that the average of all positive normalized weights is equal to
a. Clearly the optimal solution to the Target Associated k-Set problem consists of sets
A1...Ak with an objective value of k(a+ b). The greedy algorithm will pick set Ak+1 at
the first iteration and then assign a new weight to its elements equal to −a. The
updated weight of sets A1...Ak is now 0 and the algorithm will stop and output Ak+1 as
the solution, giving an approximation ratio of
kb+ 
k(a+ b)
=
1
k
+

kb
Proposition 5. If m ∈ Ω (k2 ln(n/δ)) samples from the generative model above are
provided to the greedy algorithm, then the solution of the greedy algorithm is H with
probability ≥ δ.
Proof. We prove that in iteration i of the greedy algorithm, conditioning on the current
solution being a set S with S ⊂ H, then the greedy algorithm adds a gene in H \ S to
the solution with probability ≥ delta/k, and that the first gene added by the greedy
algorithm is g ∈ H. The result then follows by union bound on the k iterations of the
greedy algorithm.
Consider the first iteration of the greedy algorithm and consider a gene g ∈ G. Note
that if g 6∈ H then E[W ({g})] ≤ 0, since E[∑j∈Ag wj ] = 0 because the samples in
which g is mutated are taken uniformly at random while
∑
j∈Ag (cS(j)− 1) ≥ 0. If
g ∈ H by the assumptions of the model we have E[W ({g})] ≥ m
kc′′′
for a constant
c′′′ ≥ 1. Note that W ({g}) can be written as the sum ∑mi=1Xi of random variables
(r.v.’s) Xi where Xi is the contribution of sample i to W ({g}) with Xi ∈ [−1, 1]. By the
Azuma-Hoeffding inequality [36] and union bound (on the n genes) the first gene chosen
by the greedy algorithm is not gene g ∈ H with probability ≤ e−
2m2
4mk2(c
′′′
)2 which is
≤ δ/k when m ∈ Ω (k2 ln(nk/δ))).
Now assume that in iteration i, for the current solution S ⊂ H. Consider a gene
g ∈ G \H, then E[W (S ∪ {g})−W (S)] ≤ 0, since
E[
∑
j∈∪s∈S∪gAs wj −
∑
j∈∪s∈SAs wj ] ≤ 0 (by the assumptions of the model W (S) > 0
and the fact that alterations in {g} are placed uniformly at random among samples)
and E[
∑
j∈∪s∈S∪g (cS(j)− 1)−
∑
j∈∪s∈S (cS(j)− 1)] ≥ 0 (because for each sample i, the
number of alterations of S ∪ {g} in i is a superset of the number of alterations of S in i).
Consider now a gene g ∈ H \ S: by the assumptions of the model
E[W (S ∪ {g})−W (S)] ≤ m
kc′′′
for a constant c
′′′
> 1. Note that E[W (S ∪ {g})−W (S)
can be written as the sum of
∑m
i=1Xi of random variables (r.v.’s) Xi where Xi is the
contribution of sample i in the increase in weight from W (S) to W (S ∪ {g}), where
Xi ∈ [−1, 1]. By the Azuma-Hoeffding inequality and union bound (on the < n genes
considered for addition by the greedy algorithm) the gene g added to S by the greedy
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algorithm in iteration i is not in H \ S with probability ≤ e−
2m2
4mk2(c
′′′
)2 which is ≤ δ/k
when m ∈ Ω (k2 ln(nk/δ))).
(a) KRAS essentiality: UNCOVER (b) KRAS essentiality: REVEALER
(c)  -catenin target: UNCOVER (d)  -catenin target: REVEALER
(e) NFE2L2 activation: UNCOVER (f) NFE2L2 activation: REVEALER
(g) MEK Inhibitor: UNCOVER(ILP) (h) MEK Inhibitor: REVEALER
(i) MEK Inhibitor: UNCOVER(Greedy)
Supplementary Figure 2: Results of UNCOVER on four cancer datasets from [?]. (a) Solution found by ILP and
greedy for KRAS essentiality target. (b) Solution found by ILP and greedy for  -catenin activation target. (c) Solution
found by ILP for MEK inihibitor target. (d) Solution found by greedy for MEK inihibitor target. (e) Solution found by
ILP and greedy for NFE2L2 activation target. Each panel shows the value of the target (top row) for various samples
(columns), with red being positive and blue being negative values. For each gene in the solution, alterations in each
sample are shown in dark blue, while samples not altered are in light blue. The last row shows the alteration profile of
the entire solution.
15
Fig 7. Results of UNCOVER and REVEALER on four cancer datasets
from [33].
(a) Solution found by ILP and greedy for KRAS essentiality target. (b) Solution found
by ILP and greedy for β-catenin activation target. (c) Solution found by ILP for MEK
inihibitor target. (d) Solution found by greedy for MEK inihibitor target. (e) Solution
found by ILP and greedy for NFE2L2 activation target. Each panel shows the value of
the target (top row) for various samples (columns), with red being positive and blue
being negative values. For each gene in the solution, alterations in each sample are
shown in dark blue, while samples not altered are in light blue. The last row shows the
alteration profile of the entire solution.
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Table 2. Solutions found when running our ILP algorithm for the Achilles dataset,
looking for positive correlation with the target. For each target we report the objective
function value for the optimal solution, the set of alterations of cardinality 3 and the
p-value computed by permutation test using 1000 permutations
target objective alterations:
VAMP7 50.19 CLYBL AMP FBXL17 DEL ARHGEF10 DEL
VHLL 43.87 ZNF705B DEL FARS2 DEL ZRANB2 DEL
TRIM13 43.75 AMY2A AMP SH3KBP1 DEL LOC649352 DEL
QDPR 43.39 DAB1 MUT SLX1A DEL RPL23AP53 DEL
CD302 43.36 FRG2C DEL LOC650623 DEL CTDP1 DEL
DDX4 43.23 LYPD8 AMP TRIM28 AMP SLC18A1 DEL
ZNF439 43.21 PLCXD3 AMP ITGA7 AMP PMP22 DEL
PTBP3 42.58 TAOK3 MUT MRPS30 AMP ALOX15 DEL
SRGAP3 42.42 FAM66B AMP SCAND3 AMP C17orf101 AMP
C10orf10 42.12 HLA-A DEL CDH12 AMP PTPRT DEL
TNIP1 42.10 LINC00547 AMP XG AMP LOC729732 DEL
PAWR 42.02 EPSTI1 AMP GPLD1 DEL DLGAP2 DEL
PRDM5 41.99 ADAD2 DEL HSD17B10 DEL IMMP2L DEL
TXNDC5 41.90 MEP1B DEL SFRP1 DEL ZNF385D DEL
TXNDC5 41.90 MEP1B DEL SFRP1 DEL ZNF385D DEL
ACSL3 41.85 RB1 MUT PLXNA4 AMP PITPNM3 DEL
ANAPC2 41.78 HERC2P3 DEL LCE1D AMP MAP1LC3A AMP
CNDP2 41.76 EPSTI1 AMP PITPNA DEL FAM86B2 DEL
MDM4 41.75 LY86-AS1 DEL THSD7B AMP LINC00583 DEL
ADCYAP1R1 41.69 HEATR4 AMP EPB41L4A DEL DLGAP2 DEL
NMBR 41.64 LOC100506136 AMPAP4S1 AMP PSPC1 DEL
PPP2R2D 41.64 LZTS1 DEL NF1P2 DEL QKI DEL
SLC39A10 41.64 OBSCN MUT LOC100302640 AMP SGSM2 DEL
GK 41.61 DST MUT ADCY8 DEL ARHGAP44 DEL
EIF4E 41.36 GUSBP9 AMP PON2 AMP CAB39L DEL
SLC31A1 41.26 FAM66E DEL TMEM132C DEL CD83 DEL
PLS3 41.24 LOC154872 AMP FAM60A AMP KRT16P2 DEL
CCT5 41.20 RASA4 DEL GUSBP1 AMP KCNQ5 DEL
FFAR2 41.17 PTPRT DEL ERICH1 DEL NBEAP1 DEL
OR4K17 41.15 THSD7B AMP C6orf201 DEL FAM86B2 DEL
TCEB1 41.09 DENND5B AMP SLC1A3 AMP SLIT3 DEL
FGD1 41.08 MLL3 MUT MIR19B1 AMP MSR1 DEL
HNRNPH3 40.99 PIK3CA MUT BCHE AMP PRDM2 DEL
EFHB 40.93 FANCM MUT WDR7 DEL RIMS2 DEL
MIF 40.90 FRG2C DEL LINC00340 DEL PPP3CC DEL
PRKY 40.85 ATP11A MUT TCEB3C DEL NFIB DEL
MGAT4C 40.81 EBF2 DEL ZNF132 DEL KRAS.G12 13 MUT
RCN2 40.54 MYLK MUT PIK3C2G MUT FAM86B1 DEL
CSE1L 40.49 LY86-AS1 DEL COL1A2 AMP GLIPR2 DEL
DGKG 40.23 MEP1B DEL PARD3B DEL MEX3C DEL
MST1R 40.20 SLC6A10P DEL GOLPH3L AMP OR52N5 DEL
TLR4 39.91 C18orf61 AMP PTEN DEL LOC728875 DEL
OR4D11 39.85 CREBBP MUT MIR4796 AMP LOC340357 DEL
CD47 39.71 STK3 AMP LOC728190 AMP NLRP1 DEL
RNF183 39.71 GPR112 MUT IFLTD1 AMP LOC340357 DEL
SULT1A3 39.68 LY86-AS1 DEL CACNA1D DEL SEC24D DEL
SULT1A4 39.68 LY86-AS1 DEL CACNA1D DEL SEC24D DEL
FGG 39.66 H3F3C AMP MSRA DEL PSG5 DEL
NFAT5 39.40 LOC286184 AMP PCTP AMP MIR4744 DEL
ANKRD5 39.40 COL14A1 AMP CXADRP2 DEL OPALIN DEL
MGP 39.37 TFAP2D AMP GAL AMP LOC728323 DEL
PDE12 39.32 HTR3C AMP GALNTL2 DEL APC.MC MUT
RAB31 39.31 IGLL5 AMP FAM106CP DEL PACRG DEL
ACTR6 39.09 DDAH1 AMP SNORD115-6 DEL LOC340357 DEL
PGLS 38.98 LOC146880 AMP EYA1 DEL GUCY1A3 DEL
MAP3K1 38.97 CDH13 DEL ME1 DEL SNTG2 DEL
SERPINA12 38.84 FLNA MUT FAM22A AMP MSR1 DEL
RWDD2A 38.79 DNAH5 AMP ESR1 AMP COLEC12 DEL
FAT2 38.10 LDLRAD3 AMP TAC1 AMP LOC440040 DEL
WSB2 36.81 MLL3 MUT CDH6 AMP CLK2 AMP
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Table 3. Solutions found when running our ILP algorithm for the Achilles dataset,
looking for negative correlation with the target. For each target we report the objective
function value for the optimal solution, the set of alterations of cardinality 3 and the
p-value computed by permutation test using 1000 permutations
target objective alterations:
KRAS 55.22 KRAS MUT TUBB8 AMP LRRC37A2 DEL
COG2 50.11 CRYZ DEL CCNY DEL KRAS.G12 13 MUT
SF3B3 46.93 GPR112 MUT SDHAP1 AMP EIF2C2 AMP
PIK3CA 45.68 PIK3CA MUT PRAMEF10 DEL TMEM232 DEL
BRAF 45.65 BRAF MUT TPGS2 DEL TRPS1 DEL
PRPF31 45.37 FBN1 MUT COL22A1 AMP MUC4 AMP
LOC100131735 45.18 TRPS1 MUT ADCY8 AMP HIPK4 AMP
SF3A3 45.07 MLL3 MUT KHDRBS3 AMP GPRC5D DEL
POLR2A 44.99 EIF2C2 AMP FYTTD1 AMP LOC100506393 DEL
GTF2F1 44.92 KIAA1409 MUT MUC4 AMP FAM135B AMP
H1FNT 44.19 CUBN MUT THSD7B AMP SLC39A14 DEL
EIF3I 43.88 MSN MUT ZFR AMP MBD2 DEL
BCLAF1 43.43 DLC1 MUT URB2 MUT FAM83H AMP
HAUS1 43.33 ABHD12 AMP HARBI1 DEL MBD2 DEL
VARS 43.13 MSN MUT CTNND2 AMP MBD2 DEL
HGS 43.10 NOSIP AMP LOC100506990 DEL FARS2 DEL
RPS12 43.03 KHDRBS3 AMP ARL11 AMP TLL2 DEL
TRIM26 42.94 LRP1B MUT GSG1L DEL RUNX1 DEL
EIF2B3 42.87 ATP7B AMP RHPN2 AMP MSRA DEL
CAND1 42.85 NOTCH1 MUT SLC6A13 AMP KBTBD11 DEL
TXNL4A 42.80 TXNRD2 AMP PTPN14 AMP CTDP1 DEL
OC90 42.78 DHRS4L2 AMP SLC6A13 AMP C8orf42 DEL
UGGT1 42.64 ZNF385B DEL NLGN1 DEL C18orf26 DEL
SRRM1 42.45 PIK3CA MUT SGK2 AMP CELA3A DEL
PSMD12 42.26 ZNF286B AMP GAGE2E DEL MBD2 DEL
SNRPF 42.25 PRKCG MUT COL22A1 AMP MUC4 AMP
OSR2 42.22 MRPS30 AMP CHEK2P2 DEL TMEM11 DEL
BUB1B 42.18 FBXO45 AMP EIF2C2 AMP POTEC AMP
ADSL 41.95 PARP1 MUT MIR19B1 AMP MIR596 DEL
ALDH9A1 41.88 LOC728323 DEL PRAMEF14 DEL KRAS.G12 13 MUT
C1QA 41.87 TPPP AMP DERA AMP TMEM11 DEL
RNF40 41.86 KALRN MUT NF1P2 DEL FAM86B2 DEL
MEST 41.76 KRAS MUT EIF3B DEL DHX38 DEL
RPAP1 41.63 EIF2C2 AMP SHKBP1 AMP LRRTM4 DEL
PRPF8 41.57 ITIH5L MUT PHF20L1 AMP SLC43A2 DEL
POLR2E 41.56 FBN1 MUT MUC4 AMP FAM135B AMP
ABCB7 41.50 ARID1A MUT RNU6-78 AMP ZNF623 AMP
POLR2F 41.38 GPR112 MUT EIF2C2 AMP MUC4 AMP
APLP1 41.37 C3orf33 AMP ERGIC3 AMP CCDC146 AMP
TSG101 41.21 NIN MUT CDH4 AMP ERBB2 AMP
CIAO1 41.20 ZNF705G AMP MIR3914-1 AMP TBC1D16 AMP
EIF2B5 41.17 FBN1 MUT SAMD12 AMP PDCD5 AMP
RANBP2 41.09 KRAS MUT TRIM49 AMP LOC731275 AMP
LOC402207 41.00 CTNNB1 MUT LOC284100 AMP LOC649352 DEL
TOMM40 40.94 EIF2C2 AMP GNAQ AMP MUC4 AMP
POLD1 40.92 MLL3 MUT FAM83H AMP ZNF91 DEL
LIG4 40.91 TFRC AMP PLA2G4F DEL CSGALNACT1 DEL
MYCBP2 40.90 FLT1 MUT LOC642426 AMP LINC00305 DEL
SOD1 40.82 ODZ1 MUT ACOT1 AMP LOC729732 DEL
MAPK4 40.77 NIPBL MUT FOXP1 DEL PITPNM3 DEL
TWISTNB 40.76 FGFR2 MUT FBXO32 AMP KRT16P2 AMP
RBMX 40.73 FBN1 MUT HPYR1 AMP HS1BP3 DEL
HBG1 40.63 KRAS MUT FRY AMP LOC148145 AMP
EIF2B4 40.58 SGK3 MUT SNORA4 AMP MBD2 DEL
RBM47 40.49 MIR4470 AMP LOC284100 AMP SETBP1 DEL
SF3A2 40.41 SETDB1 MUT LRRN3 DEL FAM90A2P DEL
NUDT1 40.39 YY1AP1 AMP ANK1 DEL NRN1 DEL
EIF3F 40.30 LRGUK MUT EIF2C2 AMP MUC4 AMP
RPS3 40.29 PIK3CA MUT LCE1C AMP MARCH8 DEL
TUBGCP3 40.28 FCGR1C AMP URI1 AMP CLDN10 DEL
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Table 4. continues
target objective alterations:
PRKRIR 40.23 KIAA1549 MUT PCAT1 AMP FAM75A1 DEL
SF3B1 40.21 FBXO32 AMP ARID3B DEL FBXW7 DEL
DDB1 40.14 RGS22 MUT THEG5 AMP WDR7 DEL
SNRPB2 40.08 ERCC6 MUT GET4 AMP DEFB109P1 DEL
BRF2 40.07 KRAS MUT CNTN5 AMP NBEAP1 DEL
POLR2C 39.98 FLNA MUT COL22A1 AMP COMMD6 AMP
POLR2D 39.98 C8orf31 AMP PRKRIR AMP MBD2 DEL
PI4KA 39.97 KRAS MUT MIR624 AMP OR4L1 DEL
ADRA1B 39.96 ODZ1 MUT PAPL AMP GTF2E2 DEL
RFX2 39.93 OBSCN MUT TBL1XR1 AMP FAM18B2 DEL
SFPQ 39.93 USP25 AMP TRIM49 AMP PYCRL AMP
PSMD13 39.92 NIN MUT VAPB AMP KIAA0825 DEL
KRR1 39.87 EVPLL AMP TNXB AMP MBD2 DEL
LGI1 39.86 SIK1 AMP CDC73 AMP FAM221A DEL
COPZ1 39.83 EIF2C2 AMP MUC4 AMP ZNF91 DEL
PDXK 39.76 COX10-AS1 DEL SNTG2 DEL OR4K5 DEL
COPS2 39.75 TRMT12 AMP BMPR2 AMP STS DEL
LSM3 39.72 ZC3H3 AMP MUC4 AMP EXOC4 DEL
APOBEC3G 39.48 SNAR-D AMP TPPP AMP APC.MC MUT
TCOF1 39.39 HCN1 AMP PTPRT DEL PRR5 DEL
RAB19 39.38 PIK3CA MUT FLJ31813 DEL MTHFD1 DEL
ZNF433 39.38 PCDH15 MUT DPF2 AMP ATP2A3 DEL
OXSM 39.26 TSHZ3 AMP C17orf101 AMP ELAC1 DEL
AP3M1 39.16 SMARCA4 MUT CALM1 AMP MBD2 DEL
PLRG1 39.14 FBN1 MUT MUC4 AMP TSTA3 AMP
SRP9 39.09 EDN3 AMP RSBN1L AMP NF2 DEL
RPS27A 39.07 NOS2 MUT TPPP AMP C17orf51 DEL
USPL1 39.01 LOC643401 AMP TOMM20 AMP ARL8B DEL
ARHGEF3 38.99 ZNF423 MUT ST6GAL1 DEL FBXO31 DEL
SNW1 38.69 MLLT3 MUT WRN MUT KIFC2 AMP
OTUD7A 38.62 DST MUT PTPN21 AMP MIR497HG DEL
FUT6 38.43 ACLY AMP FAM190A DEL ADAMTSL3 DEL
SLC25A20 38.41 DOCK3 MUT ZNF536 AMP FHOD3 DEL
EFTUD2 38.32 FBN1 MUT MUC4 AMP FAM135B AMP
IFT27 38.31 SVIL AMP C18orf26 DEL HTT DEL
PRKACG 37.98 UBE3B MUT LOC100287314 AMP ZNF705B DEL
RUFY1 37.86 AHCY AMP PRICKLE4 AMP NETO1 DEL
DHX15 37.83 KIAA2022 MUT SNAR-I AMP SERPINB11 DEL
NCBP2 37.77 GPR112 MUT FCGR3B AMP FAM135B AMP
ESPL1 36.84 GPC6 AMP CD226 DEL KALRN DEL
RPL31 36.09 PIK3CA MUT LOC643401 AMP FLJ23152 DEL
NHP2L1 35.98 CEP72 AMP CT45A3 DEL COLEC12 DEL
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Appendix
(a) ACSL3
(b) HNRNPH3
(c)MAP3K1
(d)MGAT4C
Supplementary Figure 1: Example of results of UNCOVER for Achilles dataset
12
Fig 8. Alteration matrices for results of UNCOVER the Achilles Project
data.
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